Institutional
Octagon Capital Advisors LP
CIK 0001839435
$0
Reported AUM
0
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Octagon Capital Advisors LP · Q1 2026
AI · grounded in 13F
Octagon Capital Advisors LP closed its position in ABVX, reducing its exposure by $101.95M. The fund also exited positions in DNTH and COGT, representing reductions of $99.59M and $83.47M respectively. In total, the fund reduced 27 positions during the period.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ABVX | ABIVAX SA | $101.53 | -3.24% | 1139.68% | 900.30% | — | — | −756,000 | EXITED |
| 2 | DNTH | DIANTHUS THERAPEUTICS INC | $80.51 | -4.30% | 327.11% | -29.33% | — | — | −2,416,667 | EXITED |
| 3 | COGT | COGENT BIOSCIENCES INC | $31.02 | -5.40% | 356.18% | 417.00% | — | — | −2,350,000 | EXITED |
| 4 | TSHA | TAYSHA GENE THERAPIES INC | $5.50 | -6.62% | 93.66% | -68.19% | — | — | −8,859,911 | EXITED |
| 5 | GOSS | GOSSAMER BIO INC | $0.17 | -1.69% | -86.84% | -97.77% | — | — | −13,915,371 | EXITED |
| 6 | KYMR | KYMERA THERAPEUTICS INC | $74.13 | -0.64% | 55.67% | 23.18% | — | — | −535,000 | EXITED |
| 7 | AVBP | ARRIVENT BIOPHARMA INC | $30.35 | -8.28% | 29.04% | 40.90% | — | — | −1,971,054 | EXITED |
| 8 | TRVI | TREVI THERAPEUTICS INC | $13.33 | -4.31% | 88.81% | 601.58% | — | — | −2,815,000 | EXITED |
| 9 | OCUL | OCULAR THERAPEUTIX INC | $8.25 | -6.25% | -8.54% | -25.07% | — | — | −2,623,600 | EXITED |
| 10 | BRD1EUR | MIND MEDICINE MINDMED INC | — | — | — | — | — | — | −2,230,000 | EXITED |
| 11 | CGON | CG ONCOLOGY INC | $53.72 | -4.23% | 99.63% | 20.15% | — | — | −600,000 | EXITED |
| 12 | ALMS | ALUMIS INC | $19.06 | -6.52% | 430.92% | 54.96% | — | — | −2,530,700 | EXITED |
| 13 | PALI | PALISADE BIO INC | $1.74 | -9.84% | 148.57% | -99.92% | — | — | −9,567,898 | EXITED |
| 14 | CDTX | CIDARA THERAPEUTICS INC | — | — | — | — | — | — | −100,000 | EXITED |
| 15 | BIOA | BIOAGE LABS INC | $15.70 | -7.76% | 252.81% | -33.47% | — | — | −1,598,000 | EXITED |
| 16 | KALV | KALVISTA PHARMACEUTICALS INC | $26.95 | 0.00% | 87.61% | 33.81% | — | — | −1,273,333 | EXITED |
| 17 | RAPT | RAPT THERAPEUTICS INC | — | — | — | — | — | — | −574,000 | EXITED |
| 18 | CNTA | CENTESSA PHARMACEUTICALS PLC | $39.62 | -0.45% | 232.38% | 91.96% | — | — | −750,000 | EXITED |
| 19 | PHVS | PHARVARIS N V | $31.09 | -1.71% | 85.28% | 74.96% | — | — | −671,465 | EXITED |
| 20 | LXEO | LEXEO THERAPEUTICS INC | $4.37 | -8.58% | 12.63% | -67.44% | — | — | −1,725,000 | EXITED |
| 21 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $7.81 | -5.10% | -28.28% | -24.90% | — | — | −1,043,110 | EXITED |
| 22 | DBVT | DBV TECHNOLOGIES S A | $16.59 | -5.63% | 81.71% | 59.52% | — | — | −574,200 | EXITED |
| 23 | EVMN | EVOMMUNE INC | $19.92 | -3.72% | 8.20% | 16.36% | — | — | −500,000 | EXITED |
| 24 | DTIL | PRECISION BIOSCIENCES INC | $6.50 | 1.40% | 18.40% | -97.80% | — | — | −1,917,995 | EXITED |
| 25 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $7.56 | -5.62% | -18.09% | -81.61% | — | — | −955,000 | EXITED |
| 26 | UNCY | UNICYCIVE THERAPEUTICS INC | $6.92 | -6.86% | -8.22% | -76.14% | — | — | −1,000,000 | EXITED |
| 27 | PEPG | PEPGEN INC | $1.41 | -4.73% | -6.00% | -85.80% | — | — | −700,000 | EXITED |
Source: SEC EDGAR · accession 0001839435-26-000003. 13F discloses long positions only — shorts, foreign equities, and options are excluded.